Welcome to our dedicated page for Elanco Animal Health SEC filings (Ticker: ELAN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Elanco Animal Health's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Elanco Animal Health's regulatory disclosures and financial reporting.
Simmons Jeffrey N reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health President and CEO Jeffrey N. Simmons received a grant of 118.5296 Deferred Stock Units tied to Company common stock. Each unit represents the right to receive one share or cash, settling after employment ends or in a future year under the Executive Deferral and Stock Match Plan, bringing his reported Deferred Stock Unit holdings to 24,424.9883 units.
Elanco Animal Health reported the results of its 2026 annual shareholder meeting. All nominated directors in Class I and Class II were elected to one-year terms ending at the 2027 annual meeting, with each nominee receiving substantial support in the form of several hundred million votes cast in favor.
Shareholders also ratified Ernst & Young LLP as the company’s independent registered public accounting firm for 2026, with over 480 million votes in favor. In addition, shareholders approved, on a non-binding basis, the compensation of Elanco’s named executive officers, with more than 383 million votes supporting the pay program.
Scots-Knight Denise reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health director Denise Scots-Knight received equity compensation awards rather than buying shares on the market. She was granted 12,196 deferred stock units as a pro-rated annual equity award and 4,678 restricted stock units as an annual equity award to non-employee board members.
Following these grants, her directly held common stock and stock-based awards reported in the filing total 105,588 shares for one award category and 93,392 shares for the other. These awards were granted at no cash cost per unit, reflecting standard board compensation in stock-based form.
Kurzius Lawrence Erik reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health Inc director Lawrence Erik Kurzius reported two equity awards of common stock on May 21, 2026. He received 12,196 deferred stock units as a pro-rated annual equity award and 4,678 restricted stock units as an annual equity grant for non-employee directors.
Both awards were recorded at $0.00 per share, reflecting compensation grants rather than open-market purchases.
McDonald Kirk P reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health director Kirk P. McDonald received equity compensation rather than buying shares on the market. He was granted 12,196 deferred stock units as a pro-rated annual award and 4,678 restricted stock units as an annual equity award for non-employee directors. Following these grants, the filing shows direct holdings of 105,588 and 93,392 common shares tied to the respective awards.
Elanco Animal Health director Paul Herendeen reported two equity awards in the form of common stock-based units. On May 21, 2026, he acquired 12,196 deferred stock units as a pro-rated annual equity award and 4,678 restricted stock units as an annual equity award for non-employee Board members. These are compensation-related grants at no cash cost to him, not open-market purchases or sales, and increase his equity-based stake in Elanco.
Elanco Animal Health director Deborah Turner Kochevar received an equity award of 4,678 shares of common stock on May 21, 2026. The Form 4 labels this as a grant or award acquisition at no cost per share, reported as a grant of deferred stock units for non-employee Board members. Following the award, she directly owns 94,392 shares of Elanco common stock. This is a routine director compensation grant rather than an open-market purchase.
HOOVER R DAVID reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health Inc director R. David Hoover received a grant of 4,678 shares of Common Stock as deferred stock units, described as a pro-rated annual equity award for non-employee board members. The award carried a grant price of $0.00 per share, reflecting its compensation nature rather than a market purchase.
After this grant, Hoover directly holds 111,451 shares of Elanco common stock. He also has indirect holdings reported through the Suzanne A. Hoover Revocable Trust with 15,920 shares and another Revocable Trust with 150,000 shares, providing additional indirect exposure to Elanco shares.
Harrington Michael J reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health director Michael J. Harrington reported equity awards of common stock on May 21, 2026. He received 12,196 deferred stock units as a pro-rated annual equity award and 4,678 restricted stock units as an annual equity award for non-employee board members, both at no cash cost.
Anand Kapila K reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health director Anand K. Kapila received equity compensation, not making any open-market trades. On May 21, 2026, he was granted 12,196 deferred stock units as a pro-rated annual equity award and 4,678 restricted stock units as an annual equity award for non-employee directors. Both awards were recorded at $0.00 per share, reflecting stock-based compensation rather than a purchase. After these grants, the filing reports his direct ownership of Elanco common stock at 111,847 shares.